Soluble VEGFR1, an angiogenesis inhibitor, was elevated in GBM; nevertheless, VEGFA levels were sufficiently high to diminish the soluble VEGFR1-to-VEGFA ratio, signifying enhanced VEGFA activation in GBM. The gene discussed is FLT1; the disease is glioblastoma.